Home › ImmunoGen, Inc. Announces Favorable STARLYTE Phase II Clinical Data...
 

Keywords :   


ImmunoGen, Inc. Announces Favorable STARLYTE Phase II Clinical Data...

2014-06-02 10:20:00| Logistics - Topix.net

SAR3419 is a CD19-targeting ADC developed by ImmunoGen and licensed to Sanofi as part of a broader collaboration between the companies.

Tags: data phase clinical favorable

Category:Transportation and Logistics

Latest from this category

All news
»
12.05Weekly Recap: Huggies Launches Skin Essentials Diaper, P&G Recognizes Key Suppliers & More
12.05California Bill Limits Skincare Sales to Teens & Persil Rebrands
12.05Kline Analysts Detail the Medical Dispensing Skin Care Market
12.05Glo30 Starts 2024 Strong with 60% Growth
12.05Zevo On-Body Repellent Teams with American Hiking Society To Provide Bug Bite Defense
12.05L\'Oréals Brand Value Soars to $13.4 Billion
12.05Spate Unveils the Top Sustainability Trends Cycling Google Searches
12.05Oh K! is the Most Searched Beauty Brand in the World: Cosmetify
More »